News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Ioanna Vlachaki

Articles by Ioanna Vlachaki

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

ByJavier Cortés, MD,François-Clément Bidard,Aditya Bardia, MD, MPH,Virginia G. Kaklamani, MD, DSc,Ioanna Vlachaki,Giulia Tonini,Nassir Habboubi,Philippe Aftimos

August 17th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.